Page 12 - Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma

CUAJ – Consensus Statement Mason et al
KCRNC consensus: Cytoreductive nephrectomy for mRCC

22. Capitanio U, Abdollah F, Matloob R, Salonia A, Suardi N, Briganti A, et al.
Effect of number and location of distant metastases on renal cell carcinoma
mortality in candidates for cytoreductive nephrectomy: Implications for
multimodal therapy. Int J Urol. 2013;20:572-9.
23. Corcoran AT, Kaffenberger SD, Clark PE, Walton J, Handorf E, Piotrowski Z, et
al. Hypoalbuminaemia is associated with mortality in patients undergoing
cytoreductive nephrectomy. BJU Int. 2015;116:351-7.
24. Fukushima H, Nakanishi Y, Kataoka M, Tobisu K-I, Koga F. Postoperative
Changes in Skeletal Muscle Mass Predict Survival of Patients With Metastatic
Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy. Clin Genitourin
Cancer. 2017;15:e229-e38.
25. Gu L, Li H, Wang H, Ma X, Wang L, Chen L, et al. Presence of sarcomatoid
differentiation as a prognostic indicator for survival in surgically treated
metastatic renal cell carcinoma. J Cancer Res Clin Oncol. 2017;143:499-508.
26. Ishihara H, Kondo T, Yoshida K, Omae K, Takagi T, Iizuka J, et al. Evaluation of
Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an
Independent Predictive Biomarker in Patients With Metastatic Renal Cell
Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score
Matching Study. Clin Genitourin Cancer. 2017;15:598-604.
27. Ito H, Shioi K, Murakami T, Takizawa A, Sano F, Kawahara T, et al. C-reactive
protein in patients with advanced metastatic renal cell carcinoma: usefulness in
identifying patients most likely to benefit from initial nephrectomy. BMC Cancer.
2012;12:337.
28. Kalogirou C, Mulfinger P, Sokolakis I, Krebs M, Kubler H, Riedmiller H, et al.
Preoperative C-Reactive Protein Values as a Potential Component in Outcome
Prediction Models of Metastasized Renal Cell Carcinoma Patients Receiving
Cytoreductive Nephrectomy. Urol Int. 2017;99:297-307.
29. Ohno Y, Nakashima J, Ohori M, Tanaka A, Hashimoto T, Gondo T, et al. Clinical
variables for predicting metastatic renal cell carcinoma patients who might not
benefit from cytoreductive nephrectomy: neutrophil-to-lymphocyte ratio and
performance status. Int J Clin Oncol. 2014;19:139-45.
30. Pierorazio PM, McKiernan JM, McCann TR, Mohile S, Petrylak D, Benson MC.
Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is
predicted by fractional percentage of tumour volume removed. BJU Int.
2007;100:755-9.
31. Sharma P, Zargar-Shoshtari K, Caracciolo JT, Fishman M, Poch MA, Pow-Sang
J, et al. Sarcopenia as a predictor of overall survival after cytoreductive
nephrectomy for metastatic renal cell carcinoma. Urol. 2015;33:339.e17-23.